Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Congenital Myotonic Dystrophy: early-phase trial registry

5 of 5 indexed Congenital Myotonic Dystrophy trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 5 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Congenital Myotonic Dystrophy: 5 US clinical trials tracked, 5 recruiting.

Congenital Myotonic Dystrophy is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Virginia Commonwealth University, running 2 of these trials.

Enrollment posture brief

Registry condition congenital-myotonic-dystrophy

OPEN 5 | RECR 100% | LATE 0 | EARLY 1 | RANK #3391 | SPON 2

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Congenital Myotonic Dyst (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Congenital Myotonic Dystrophy

Congenital Myotonic Dystrophy lists 5 open slots (100% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Congenital Myotonic Dystrophy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Congenital Myotonic Dystrophy is recruiting above its size-band peers.

    5 of 5 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Congenital Myotonic Dystrophy research.

    Virginia Commonwealth University accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Typical Congenital Myotonic Dystrophy enrolment sits around 200 participants.

    Median target enrolment is 200 among the 5 trials that report a genuine target (sentinel values excluded). 2 of those (40%) plan for fewer than 100 participants.

  4. Congenital Myotonic Dystrophy research leans observational.

    1 interventional and 4 observational studies make up this index (20% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Congenital Myotonic Dystrophy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Patient-entered data Other
1 trials
Tideglusib Drug
1 trials

US sites by state

Facility locations filed on Congenital Myotonic Dystrophy trials. A trial with sites in several states counts in each.

Virginia 3 trials
New York 3 trials
California 3 trials
Utah 1 trials
Pennsylvania 1 trials
Kansas 1 trials
Illinois 1 trials
Iowa 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Congenital Myotonic Dystrophy page

5 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Congenital Myotonic Dystrophy condition card totals 5 registered trials; most-linked intervention Patient-entered data; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.